FTC Lawsuit on High Insulin Prices and Its Impact on American Households


September 21, 2024 09:00 AM PDT

(PenniesToSave.com) – The Federal Trade Commission (FTC) has recently filed a lawsuit against three major pharmacy benefit managers (PBMs) for allegedly inflating the prices of insulin, a life-saving medication for millions of Americans. The lawsuit accuses Caremark, Express Scripts, and OptumRx of manipulating a rebate system that drove up insulin costs, leaving many families struggling to afford this essential drug.

What the FTC Lawsuit Alleges

The FTC’s complaint targets the “Big Three” PBMs—Caremark, Express Scripts, and OptumRx—claiming they abused their power by creating a system that prioritized high-cost insulins to maximize their profits. According to the lawsuit, these companies used their market dominance to exclude cheaper insulin options in favor of more expensive, highly rebated products. This practice, the FTC argues, has contributed significantly to the soaring cost of insulin over the past two decades, making it harder for many Americans to access this critical medication.

The Financial Impact on American Families

For families dealing with diabetes, high insulin prices can be devastating. A decade ago, insulin costs were relatively manageable, but today, many patients face skyrocketing expenses. The average list price for a common insulin product, Humalog, has increased from $21 in 1999 to hundreds of dollars today. These inflated prices force families to make tough choices, often leading to rationing or skipping doses, which can have severe health consequences.

The lawsuit highlights how these business practices have shifted costs onto vulnerable patients, making it clear that the issue is not just about high prices but about access to essential healthcare.

Broader Implications of the Lawsuit

This lawsuit could be a turning point in the fight against high drug prices. If successful, the FTC’s action could lead to significant changes in how PBMs operate, potentially lowering the cost of not only insulin but other medications as well. By addressing the root cause of inflated drug prices, the lawsuit aims to restore competition in the pharmaceutical market, which could benefit all consumers.


The case also raises awareness about the opaque and often unregulated role of PBMs in drug pricing. Increased scrutiny on these entities may prompt further regulatory action, potentially reshaping the entire industry.

What This Means for American Households

For the average American household, this lawsuit represents a glimmer of hope in the struggle against rising healthcare costs. If the FTC succeeds, families could see reduced insulin prices, easing the financial burden on millions of households. Lower drug prices could also mean more predictable healthcare expenses, allowing families to budget more effectively without sacrificing essential medications.

Moreover, the lawsuit could set a precedent for tackling other high-cost drugs, benefiting a broader range of patients. For now, families should stay informed and advocate for policies that ensure affordable access to life-saving medications.

Final Thoughts

The FTC’s lawsuit against major PBMs over high insulin prices is a crucial step toward addressing a broken system that has placed undue financial stress on many American families. While the outcome of the lawsuit is uncertain, its potential to lower drug prices and increase access to essential medications is significant. For families struggling with the high cost of insulin, this legal action could be a much-needed reprieve.

Reference